Numerous pharmaceutical firms have canceled or postponed significant expansions of UK R&D facilities, prompting worries regarding the UK’s appeal for life science investments. Merck & Co. terminated a £1 billion project in London, whereas AstraZeneca put a £200 million expansion of its Cambridge site on hold. Eli Lilly and Sanofi have also reevaluated their UK […]
Read More